Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 1997

View Archived Issues

Arris and Bayer modify collaboration

Ganciclovir implant effective in treating CMV retinitis

Future therapeutic targets for AD

Company Profile: Biorex

Merck Sharp & Dohme reveals new tachykinin antagonists

HIV protease inhibitors from Novartis

Acetylcholine receptor modulators reported by SIBIA Neurosciences

Biomedica Foscama discloses adenosine antagonists for depression

Potent, orally active fibrinogen antagonist developed at Merck & Co.

Novel antiinflammatory agents prepared by French investigators

FDA approves first medical device for epilepsy

Cell Pathways reports chemoprotective activity of sulindac sulfone in animal model

Preliminary results from IMpact-RSV trial

Low-dose interferon alfa nears phase III for the treatment of Sjogren's syndrome

Mycophenolic acid derivatives with immunosuppressive activity claimed

Final dosimetry analysis of phase II/III trial of Oncolym

Kanebo reports novel cell adhesion inhibitors

RiboGene and Trega Biosciences extend drug discovery collaboration

FK-143: promising new BPH therapy

Fibrinogen-antagonistic oxopiperazine derivatives from Yamanouchi

Nisshin Flour Milling describes new antiasthma drugs

New cardiovascular drugs reported by Yamanouchi

Preliminary results reported for lisofylline in acute myeloid leukemia phase II trial

RS-67506 enhances lower intestinal propulsion in mice

Possible mechanism of antiarthritic activity of TA-383 reported

SIGA and Wyeth-Ayerst commence discovery program for novel antiinfectives

Dose-response trial of LAAM in opioid-dependent subjects

Promising preliminary results reported for Interneuron's ischemic stroke treatment

Isis and Ciba Vision sign distribution agreement for novel CMV retinitis drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...